Ed Cinca is the Senior Vice President of Marketing & Patient Solutions at Novo Nordisk Inc., a role he assumed in September 2025. In this role, Ed guides the US commercial strategy and marketing execution for Novo Nordisk’s cardiometabolic portfolio and leads a team dedicated to improving health outcomes for millions of people who can benefit from Novo Nordisk medicines in the US, including delivering a best-in-class experience for both patients and healthcare providers.

An accomplished leader in the pharmaceutical industry with a proven track record in product launches, commercialization, and business transformation, Ed excels in go-to-market strategy, consistently exceeds P&L goals, and positions businesses for sustained growth. He has extensive experience across sales, marketing, market access, and operations, with a deep understanding of both local and global product execution.

From 2003 to 2021, Ed held several leadership roles at Novo Nordisk Inc., including Vice President and Head of the Cardiometabolic Portfolio, where he led the launches of Ozempic^®, Rybelsus^®, and Wegovy^®. He also served as Vice President, Sales Execution and Operations, and Senior Brand Director for Saxenda^®.

Prior to rejoining Novo Nordisk, Ed was the Chief Commercial Officer at Radius Health where he led the full commercial organization and P&L, transforming the business from decline to sustained double-digit growth from 2022–2025. He also served as Senior Vice President and General Manager at Currax Pharmaceuticals, LLC.

Ed holds an MBA in Marketing and Finance from Fordham University, a Bachelor of Science in Finance from Lehigh University, and an Executive Education certificate from The Wharton School of the University of Pennsylvania. Ed has served on the American Diabetes Association Board of Directors for the NYC/NJ Chapter and has chaired its largest annual fundraiser since 2011. He is fluent in Spanish and is committed to mentoring talent and giving back to his community.